Myriad Genetics, Inc. (NASDAQ:MYGN) insider Alexander Ford sold 3,031 shares of the business’s stock in a transaction dated Monday, November 13th. The shares were sold at an average price of $31.64, for a total value of $95,900.84. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Shares of Myriad Genetics, Inc. (MYGN) traded up $0.92 during midday trading on Tuesday, reaching $32.47. The company’s stock had a trading volume of 1,073,900 shares, compared to its average volume of 1,221,741. The company has a debt-to-equity ratio of 0.09, a quick ratio of 2.06 and a current ratio of 2.34. The firm has a market capitalization of $2,184.55, a P/E ratio of 28.94, a price-to-earnings-growth ratio of 2.02 and a beta of 0.24. Myriad Genetics, Inc. has a 12-month low of $15.15 and a 12-month high of $37.30.

Myriad Genetics (NASDAQ:MYGN) last issued its earnings results on Tuesday, November 7th. The company reported $0.26 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.21 by $0.05. The firm had revenue of $190.20 million during the quarter, compared to the consensus estimate of $183.52 million. Myriad Genetics had a return on equity of 9.54% and a net margin of 13.28%. The business’s quarterly revenue was up 7.2% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.23 earnings per share. equities research analysts forecast that Myriad Genetics, Inc. will post 1.04 EPS for the current year.

COPYRIGHT VIOLATION NOTICE: This article was originally posted by American Banking News and is the sole property of of American Banking News. If you are accessing this article on another site, it was illegally stolen and reposted in violation of United States & international trademark & copyright law. The legal version of this article can be viewed at https://www.americanbankingnews.com/2017/11/14/alexander-ford-sells-3031-shares-of-myriad-genetics-inc-mygn-stock.html.

Several institutional investors have recently added to or reduced their stakes in the company. BlackRock Inc. increased its stake in shares of Myriad Genetics by 168,335.7% in the first quarter. BlackRock Inc. now owns 9,541,884 shares of the company’s stock valued at $183,203,000 after buying an additional 9,536,219 shares during the period. Vanguard Group Inc. increased its stake in shares of Myriad Genetics by 0.9% in the second quarter. Vanguard Group Inc. now owns 6,307,738 shares of the company’s stock valued at $162,992,000 after buying an additional 56,708 shares during the period. Dimensional Fund Advisors LP increased its stake in shares of Myriad Genetics by 4.4% in the third quarter. Dimensional Fund Advisors LP now owns 3,580,081 shares of the company’s stock valued at $129,527,000 after buying an additional 149,865 shares during the period. Thrivent Financial For Lutherans increased its stake in shares of Myriad Genetics by 7,026.7% in the second quarter. Thrivent Financial For Lutherans now owns 2,742,340 shares of the company’s stock valued at $70,862,000 after buying an additional 2,703,860 shares during the period. Finally, Northern Trust Corp increased its stake in shares of Myriad Genetics by 31.1% in the second quarter. Northern Trust Corp now owns 1,292,588 shares of the company’s stock valued at $33,400,000 after buying an additional 306,276 shares during the period.

A number of research analysts recently commented on the company. Morgan Stanley reaffirmed an “underweight” rating and issued a $24.00 price target (up previously from $17.00) on shares of Myriad Genetics in a research note on Friday, October 6th. Leerink Swann reaffirmed a “market perform” rating and issued a $31.00 price target on shares of Myriad Genetics in a research note on Monday, October 2nd. Zacks Investment Research raised Myriad Genetics from a “hold” rating to a “strong-buy” rating and set a $42.00 price target for the company in a research note on Tuesday, October 17th. Stephens reaffirmed an “overweight” rating and issued a $40.00 price target (up previously from $36.00) on shares of Myriad Genetics in a research note on Friday, September 22nd. Finally, Cowen and Company reaffirmed a “hold” rating and issued a $25.00 price target on shares of Myriad Genetics in a research note on Sunday, September 17th. Two investment analysts have rated the stock with a sell rating, seven have given a hold rating, three have given a buy rating and one has given a strong buy rating to the stock. Myriad Genetics presently has an average rating of “Hold” and a consensus price target of $28.10.

About Myriad Genetics

Myriad Genetics, Inc is a molecular diagnostic company. The Company is engaged in the discovery, development and marketing of transformative molecular diagnostic tests. The Company operates through two segments: diagnostics and other. The diagnostics segment provides testing and collaborative development of testing that is designed to assess an individual’s risk for developing disease later in life, identify a patient’s likelihood of responding to drug therapy and guide a patient’s dosing to enable optimal treatment, or assess a patient’s risk of disease progression and disease recurrence.

Receive News & Ratings for Myriad Genetics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myriad Genetics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.